US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Replimune Group Inc
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
June 01, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
May 29, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
May 22, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
May 16, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 09, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
February 12, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 07, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
January 21, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
January 08, 2025
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Pricing of Upsized Public Offering
November 25, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Proposed Public Offering
November 25, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
November 21, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 09, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 08, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 30, 2024
From
Replimune Group Inc
Via
GlobeNewswire
Tickers
REPL
